- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01303770
Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis
Multiple sclerosis (MS) is a progressive neurological disease that affects over 2.5 million people worldwide. Up to 50% of persons with MS (PwMS) will experience some form of cognitive impairment as a result of the disease including disturbances in memory, attention, concentration, information processing, and executive functions such as problem solving, and self-monitoring. MS-related cognitive impairments negatively affect many aspects of functioning and independent participation in everyday life. Thus, PwMS who experience cognitive impairments face a wide array of recurring barriers that pose grave challenges to carrying out everyday activities while trying to maintain multiple life roles and as they age.
Management of cognitive symptoms can be addressed through rehabilitation which has the potential to reduce disability, prevent complications of the disease, and enhance participation, independence, and quality of life. Considering the high frequency of cognitive impairments in MS and their significant, complex impact on functioning and independence, it is critical that cognitive interventions be an essential component of MS rehabilitation.
The overarching goal of this study is to develop and test a self-management, group-based cognitive rehabilitation program designed specifically for PwMS.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petah Tikva, Israel, 49100
- Rabin Medical Center, Multiple Sclerosis Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of MS
- 18 years of age or older
- Self-report of cognitive difficulties
Exclusion Criteria:
- Exacerbation of symptoms in past 3 months
- History of TBI, CVA, epilepsy, Psychiatric condition, drug/alcohol abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control group
|
8-week group program that is not specifically directed to management of cognitive impairments.
|
|
Experimental: Cognitive intervention group
Cognitive rehabilitation program designed to be tested in this study
|
8-week cognitive rehabilitation program facilitated by an occupational therapist.
Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognitive strategy use
Time Frame: pre intervention, post intervention, 3,6,12 month followup
|
pre intervention, post intervention, 3,6,12 month followup
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognitive self-efficacy
Time Frame: pre-intervention, post intervention, 3,6,12 month followup
|
pre-intervention, post intervention, 3,6,12 month followup
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eynat Shevil, PhD, Tel Aviv University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neurocognitive Disorders
- Cognition Disorders
- Multiple Sclerosis
- Sclerosis
- Cognitive Dysfunction
Other Study ID Numbers
- MSCogRehab
- PIRG03-GA-2008-230959 (Other Grant/Funding Number: European Commission FP7 Marie Curie IRG)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.